The impact of Daratumumab on transfusion service costs.
Melissa M CushingRobert A DeSimoneRuchika GoelYen-Michael Sheng HsuPriscilla ParraSabrina E Racine-BrzostekDiana DegtyaryovaDian T LoMeta MorrisonKathleen M CrowleyAdrianna RossiLjiljana V VasovicPublished in: Transfusion (2019)
In our entire cohort of DARA patients, a DTT-based testing algorithm with selective genotyping and provision of phenotypically similar RBCs only for patients with clinically significant antibodies was less expensive than a simulated model of universal genotyping and provision of phenotypically similar RBCs.